

### Remarks/Arguments


Claims 43-81 are pending in the present application and are subject to a restriction requirement. In response to an earlier restriction requirement, communicated in an Office Action mailed on April 12, 2007, Applicants elected claims 43-81, species 1, SEQ ID NOs: 1 and 2 for examination in the present application. The earlier restriction requirement has now been vacated, and Applicants are requested to elect one of the inventions designated as Groups 1-22 on pages 2 and 3 of the Office Action.

Applicants hereby elect the invention of Group 5, claims 43-60, and 62-81, drawn to a method for treating a central nervous system cancer cell, using an antibody to SEQ ID NO: 2, without traverse.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No.: 39766-0294R1). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully Submitted,

Date: February 11, 2008

  
Ginger R. Dreger  
Reg. No. 33,055

**HELLER EHRMAN LLP**  
**Customer No. 25213**  
275 Middlefield Road  
Menlo Park, CA 94025  
Tel: (650) 324-7000  
Fax: (650) 324-0638